Literature DB >> 9812920

NO inhibits cytokine-induced iNOS expression and NF-kappaB activation by interfering with phosphorylation and degradation of IkappaB-alpha.

K Katsuyama1, M Shichiri, F Marumo, Y Hirata.   

Abstract

Nitric oxide (NO) is known to have antiatherogenic and anti-inflammatory properties, but its effects on the cytokine-induced nuclear factor-kappa B (NF-kappaB) activation pathway in relation to the regulation of inducible nitric oxide synthase (iNOS) gene in vascular smooth muscle cells (VSMCs) remain elusive. To elucidate the roles of NO in the regulation of cytokine-induced NF-kappaB activation and consequent iNOS gene expression, we studied the effects of NO donors [(+/-)-(E)-ethyl-2-[(E)-hydroxyamino]-5-nitro-3-hexeneamide (NOR3) and sodium nitroprusside] on interleukin (IL)-1beta-induced NF-kappaB activation and IkappaB-alpha degradation and subsequent iNOS expression in rat VSMCs. Northern blot and Western blot analyses demonstrated that NO donors decreased IL-1beta-induced iNOS mRNA and protein expression. Electrophoretic mobility shift assay using synthetic oligonucleotide corresponding to the downstream NF-kappaB site of rat iNOS promoter as a probe showed that NOR3 inhibited IL-1beta-induced NF-kappaB activation and its nuclear translocation, as demonstrated with immunocytochemical study. These effects were independent of guanylate cyclase activation; an inhibitor of soluble guanylate cyclase (1H-oxadiazolo-1,2,4-[4,3-alpha]quinoxaline-1-one) had no effect on NOR3-induced inhibition of NF-kappaB activation or iNOS mRNA expression by IL-1beta, and a cGMP derivative (8-bromo-cGMP) failed to mimic the effects of NO donors. Western blot analysis using anti-IkappaB-alpha and anti-phospho-IkappaB-alpha antibodies revealed that IL-1beta induced a transient degradation of IkappaB-alpha preceded by a rapid appearance of phosphorylated IkappaB-alpha, both of which were completely blocked by NOR3. A proteasome inhibitor (MG115) blocked IL-1beta-induced transient degradation of IkappaB-alpha and stabilized the appearance of phosphorylated IkappaB-alpha stimulated by IL-1beta. NOR3 inhibited the appearance of IL-1beta-induced phosphorylated IkappaB-alpha even in the presence of MG115. Our results indicate that an inhibitory action by NO on cytokine-induced NF-kappaB activation and iNOS gene expression is due to its direct blockade on phosphorylation and subsequent degradation of IkappaB-alpha via the cGMP-independent pathway in rat VSMCs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9812920     DOI: 10.1161/01.atv.18.11.1796

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  38 in total

Review 1.  New concepts in vascular nitric oxide signaling.

Authors:  R A Oeckler; M S Wolin
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

2.  21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties.

Authors:  M Paul-Clark; P Del Soldato; S Fiorucci; R J Flower; M Perretti
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 3.  The ubiquitin-proteasome system and cardiovascular disease.

Authors:  Saul R Powell; Joerg Herrmann; Amir Lerman; Cam Patterson; Xuejun Wang
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

4.  Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis.

Authors:  Mark J Paul-Clark; Lucia Mancini; Piero Del Soldato; Roderick J Flower; Mauro Perretti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 5.  The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.

Authors:  Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2018-02-14       Impact factor: 5.858

6.  NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes.

Authors:  P Minuz; M Degan; S Gaino; A Meneguzzi; V Zuliani; C L Santonastaso; P D Soldato; A Lechi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

7.  Enhanced anti-inflammatory potency of a nitric oxide-releasing prednisolone derivative in the rat.

Authors:  Fusun Turesin; Piero del Soldato; John L Wallace
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

8.  S-nitroso human serum albumin given after LPS challenge reduces acute lung injury and prolongs survival in a rat model of endotoxemia.

Authors:  A Jakubowski; N Maksimovich; R Olszanecki; A Gebska; H Gasser; B K Podesser; S Hallström; S Chlopicki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-15       Impact factor: 3.000

9.  Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications.

Authors:  Assunta Pandolfi; Elena Anna De Filippis
Journal:  Genes Nutr       Date:  2007-10-17       Impact factor: 5.523

10.  Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression.

Authors:  J Jankowski; M van der Giet; V Jankowski; S Schmidt; M Hemeier; B Mahn; G Giebing; M Tolle; H Luftmann; H Schluter; W Zidek; M Tepel
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.